Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Clinical trial NCT02968563 · COMPLETED
Trial details
- NCT number
- NCT02968563
- Sponsor
- Gilead Sciences
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-12-13
- Primary completion
- 2019-06-17
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.